jan 29, 2015 - > BEST 2 (1100 participants) Primary objectives: accuracy Result: 1. 93.3% participants successfully swallowed Cytosponge; cytosponge was favoured over endoscopy 2. Sensitivity = 79.9% (overall); 87.2% (patients with ≥3 cm of circumferential BE); 89.7% (patients who swallowed Cytosponge twice) 3. Specificity = 92.4% Conclusion: Cytosponge-TFF3 is safe and acceptable; simple and inexpensive.

Description:

Primary objectives: safety, acceptability, accuracy
Study design: case-control study in 11 UK hospitals. Endoscopy as gold standard.
Participants: 463 controls (dyspepsia and reflux symptoms); 647 Barrett's Oesophagus cases
Method: Participants swallow Cytosponge prior to endoscopy
Data collection time: July 2011 to December 2013
Limitations:
1. Results are not generalizable due to the nature of case-control study
2. Acceptability data were limited to a single measure

Funding: The BEST2 study was funded by Cancer Research UK in its entirety (Grant ref; C14478/A12088, http://www.cancerresearchuk.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Added to timeline:

Date: